A Multicenter Clinical Trial On the Use of Complexed Prostate Specific Antigen in Low Prostate Specific Antigen Concentrations
Abstract
Purpose:
The determination of complexed prostate specific antigen (cPSA) has been suggested to be promising for prostate cancer (PCa) diagnosis. In a multicenter trial we evaluate the diagnostic use of PSA forms in the low total PSA (tPSA) range.
Materials and Methods:
A total of 283 white men with and 417 without PCa and tPSA concentrations between 0 and 6 ng/ml were retrospectively analyzed. All 700 untreated subjects underwent a multisector needle biopsy of the prostate. The Elecsys analyser 1010 (Roche Diagnostics, Mannheim, Germany) was used for determination of tPSA and free PSA. Determination of cPSA and tPSA was performed using immunoassays of the Bayer Immuno 1 system (Bayer Diagnostics, Tarrytown, New York).
Results:
Receiver operating characteristics analyses for discrimination between cases with and without PCa were performed. The areas under the curves (AUC) for cPSA, tPSA and free-to-total PSA (f/tPSA) showed no significant differences in the tPSA ranges of 0 to 6 (700 cases), 0 to 4 (510) and 0.5 to 2.5 ng/ml (253). Within the tPSA range of 2.5 to 4 ng/ml (230 cases) the AUC for cPSA (0.61) was significantly larger than that for tPSA (Roche 0.51, Bayer 0.54) but did not differ from the AUC of f/tPSA (Roche). On the basis of the cutoffs for 95% specificity or sensitivity, no significant increase in corresponding sensitivity or specificity was found between tPSA with cPSA.
Conclusions:
In the tPSA range of less than 4 ng/ml no improvement in diagnostic accuracy was shown between cPSA with tPSA or the ratio of f/tPSA. The search for a useful marker in the low PSA range must continue.
References
- 1 : Cancer statistics, 2003. CA Cancer J Clin2003; 53: 5. Google Scholar
- 2 : A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA1995; 273: 289. Google Scholar
- 3 : Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology1999; 54: 220. Google Scholar
- 4 : Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol1999; 162: 293. Link, Google Scholar
- 5 : Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL. Urology1999; 53: 945. Google Scholar
- 6 : PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology1999; 54: 517. Google Scholar
- 7 : Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology2000; 55: 791. Google Scholar
- 8 : Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem1998; 44: 1216. Google Scholar
- 9 : Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology1998; 52: 372. Google Scholar
- 10 : Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol2002; 167: 2017. Link, Google Scholar
- 11 : Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. Eur Urol2001; 39: 57. Google Scholar
- 12 : Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. Prostate2000; 42: 181. Google Scholar
- 13 : Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol2001; 165: 1930. Link, Google Scholar
- 14 : Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?. Int J Cancer2001; 93: 759. Google Scholar
- 15 : Prostate cancer detection at low prostate specific antigen. J Urol2000; 163: 806. Link, Google Scholar
- 16 : Measurement of the complex between prostate-specific antigen and alpha1 protease inhibitor in serum. Clin Chem1999; 45: 814. Google Scholar
- 17 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998; 279: 1542. Google Scholar
- 18 : Can complexed PSA be used as a single test for detecting prostate cancer?. Urology1999; 54: 4. Google Scholar
- 19 : RE: A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer (letter to the editor). J Urol2002; 167: 259. Link, Google Scholar
- 20 : Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology2002; 60: 31. Google Scholar
From the Departments of Urology, University Hospital Charité, Humboldt University Berlin, University Hospital, Münster, University Hospital Eppendorf, Hamburg and Medical School Essen, Essen, Germany, and Kantonsspital Aarau, Aarau, Switzerland
